Search Within

William Douglas Tap

Formats
  1. Journal Article (191)
  2. Meeting Abstract (159)
  3. Review (11)
  4. Book Section (4)
  5. Editorial (4)
  6. Guidelines (3)
  7. Miscellaneous (2)
  8. Research Letter (1)
Groups
  1. Department of Medicine (375)
  2. Sarcoma Service (375)
  3. Solid Tumor Oncology Division (375)
  4. GSK Faculty (158)
  5. Tow Center for Developmental Oncology (TCDO) (148)
  6. Department of Pathology and Laboratory Medicine (132)

More Groups

People
  1. Sandra D'Angelo (105)
  2. Cristina Antonescu (96)
  3. Mark Dickson (91)
  4. Samuel Singer (80)
  5. Mrinal Gounder (78)
  6. Mary Keohan (76)

More People

Years
  1. 2025 (17)
  2. 2024 (50)
  3. 2023 (34)
  4. 2022 (43)
  5. 2021 (25)
  6. 2020 (34)

More Years

Publications
  1. Journal of Clinical Oncology (102)
  2. Annals of Oncology (30)
  3. Clinical Cancer Research (27)
  4. Cancer Research (14)
  5. Modern Pathology (11)
  6. Lancet Oncology (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (109)
  2. American Association for Cancer Research (48)
  3. Oxford University Press (38)
  4. Elsevier Science, Inc. (22)
  5. Elsevier Inc. (20)
  6. Nature Publishing Group (19)

More Publishers

Results (375)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor mitotic rate after neoadjuvant imatinib is associated with outcome in primary gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Cavnar, M. J.; Seier, K.; Mithat, G.; Balachandran, V. P.; Curtin, C.; Keohan, M.; Tap, W.; Antonescu, C.; Singer, S.; DeMatteo, R. P.
    Annals of Surgical Oncology (2019)

    Fulltext@MSK | Save
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
    Journal Article

    Jones, R. L.; Mo, G.; Baldwin, J. R.; Peterson, P. M.; Ilaria, R. L. Jr; Conti, I.; Cronier, D. M.; Tap, W. D.
    Cancer Chemotherapy and Pharmacology (2019)

    Fulltext@MSK | Save
  • Soft tissue sarcoma
    Book Section

    Singer, S.; Tap, W. D.; Kirsch, D. G.; Crago, A. M.
    In DeVita, V. T. Jr; Lawrence, T. S.; Rosenberg, S. A. (Eds.) DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed (2019)

    Fulltext@MSK | Save
  • Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT)
    Meeting Abstract

    Tap, W. D.; Gelderblom, H.; Stacchiotti, S.; Palmerini, E.; Ferrari, S.; Desai, J.; Bauer, S.; Blay, J. Y.; Alcindor, T.; Ganjoo, K. N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Wagner, A. J.; Tap, W. D.; Shields, A. F.; Patnaik, A.; Chugh, R.; Tinoco, G.; Michelson, G.; Alcantar, O.; Pelayo, M.; Zhang, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma
    Meeting Abstract

    Ravi, V.; Brohl, A. S.; Chawla, S. P.; Attia, S.; Riedel, R. F.; Liebner, D. A.; Thornton, K. A.; Mallick, A. B.; Mehta, C. R.; Liu, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS)
    Meeting Abstract

    Ravi, V.; Brohl, A. S.; Chawla, S. P.; Attia, S.; Riedel, R. F.; Liebner, D. A.; Thornton, K. A.; Mallick, A. B.; Davis, D. W.; Cervantes, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma
    Meeting Abstract

    Kelly, C. M.; Bowler, T. G.; Munhoz, R. R.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Dholakia, R.; Condy, M. M.; Singer, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L)
    Meeting Abstract

    Bauer, T. M.; Gounder, M. M.; Weise, A. M.; Schwartz, G. K.; Carvajal, R. D.; Kumar, P.; Zernovak, O.; Beck, A.; Doyle, J.; Mendell-Harary, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save